Breaking Finance News

RBC Capital covered K2M Group (NASDAQ:KTWO), stepping up its target to $23.00 earlier today

Displaying a price of $18.40, K2M Group (NASDAQ:KTWO) traded 1.38% higher on the day. With the last stock price close up 19.10% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same period. The company has recorded a 50-day moving average of $16.94 and a 200-day moving average of $15.45. 150,070 shares of K2M Group exchanged hands, down from an avg. volume of 275,085

K2M Group (NASDAQ:KTWO) had its price target bumped up to $23.00 by RBC Capital in a report issued 10/10/2016. The increased price target implies a potential upside of 0.25% from the company's last stock close price.

Previously on 10/5/2016, Zacks Investment Research released a statement about K2M Group (NASDAQ:KTWO) raised the target price from $0.00 to $20.00 that suggested an upside of 0.11%.

Performance Chart


K2M Group has a one year low of $10.10 and a one year high of $21.67 K2M Group’s market capitalization is presently $0.

Also covering K2M Group's price target, a total of 7 firms have issued a report on the company. The average stock price target is $20.43 with 0 firms rating the stock a strong buy, zero analysts rating the company a buy, 0 brokerages rating the company a hold, zero brokerages rating the stock a underperform, and finally 0 equity analysts rating the company a sell.

Brief Synopsis About K2M Group (NASDAQ:KTWO)

K2M Group Holdings, Inc. is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company's spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions. Its products consist of implants, disposables and instruments, which are marketed and sold primarily to hospitals for use by spine surgeons. The Company's product portfolio contains over 70 product lines that are used in spine surgeries, minimally invasive spine (MIS) and degenerative surgeries. It markets or sells its products in the United States and over 36 other countries. The Company's technologies include MESA, Rail 4D, Quicket Deformity, CAPRI, SERENGETI, RAVINE, EVEREST, CASCADIA and tifix.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *